Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Mesothelioma Clinical Trials

A listing of Mesothelioma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (41) clinical trials

FR901228 and Flavopiridol in Treating Patients With Advanced Lung Esophageal or Pleural Cancer

OBJECTIVES: Primary - Determine the maximum tolerated dose and dose-limiting toxic effects of FR901228 (depsipeptide) when administered with flavopiridol in patients with advanced primary lung or esophageal cancer, malignant pleural mesothelioma, or lung or pleural metastases. - Determine the pharmacokinetics of this regimen in these patients. Secondary - Analyze gene ...

Phase

Study of Patients With Non-Small Cell Lung Cancer Esophageal Cancer Malignant Pleural Mesothelioma Mediastinal or Chest Wall Neoplasms or Lung Metastases From Cancers of Non-Thoracic Origin

OBJECTIVES: - Evaluate patients referred to the Thoracic Oncology Section of the Surgery Branch, NCI in order to identify patients who are suitable candidates for clinical research protocols. - Obtain biopsies during staging studies of tumor and adjacent normal tissues as well as serum and urine samples from patients with ...

Phase N/A

Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis

DISEASE CHARACTERISTICS: - Histologically confirmed peritoneal carcinomatosis with the following histologies: - Primary peritoneal mesothelioma - Adenocarcinoma of gastrointestinal tract origin - Confined to peritoneal cavity - Tumor mass could be debulked to less than 2.5 cm in diameter per tumor deposit - Must not have failed prior intraperitoneal platinum ...

Phase

Immunotoxin Therapy Pemetrexed and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery

OBJECTIVES: Primary - To estimate the maximum-tolerated dose (MTD) of SS1(dsFv)-PE38 immunotoxin when administered with pemetrexed disodium and cisplatin and to establish a safe dose, based on the MTD for subsequent clinical testing (phase II recommended dose) in patients with unresectable malignant epithelial pleural mesothelioma. - To characterize the toxicity ...

Phase

N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy

Background of the study: Cisplatin (CDDP) is a major compound in chemotherapy in patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and malignant mesothelioma. Cisplatin is associated with a number of side-effects, one of which is neurotoxicity. For a number of patients this neurotoxicity is a ...

Phase N/A

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung Esophagus and Lung Lining

Background: -Lung and esophageal cancers as well as malignant pleural mesotheliomas exhibit profound alterations in chromatin structure, which may impact the clinical course of these neoplasms. -To date, epigenetic alterations in primary thoracic malignancies and neoplasms metastatic to the chest have not been evaluated in a systematic manner. Objectives: - ...

Phase N/A

An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma

This is a non-randomized, multicenter, open label, single agent phase II study. Patients with malignant mesothelioma that has recurred or progressed following chemotherapy, and who qualify for this study, will receive milataxel 60 mg/m2 orally on Day 1 of a 21 day cycle. If no toxicities of greater than Grade ...

Phase